Lanean...
Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
The effect of switching from originator infliximab to biosimilar infliximab in patients with sarcoidosis is unknown. The objective of this study is to investigate the effect of switching from Remicade(®) or Inflectra(®) to Flixabi(®) in patients with severe refractory sarcoidosis. This single center...
Gorde:
| Argitaratua izan da: | Cells |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7922542/ https://ncbi.nlm.nih.gov/pubmed/33669641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells10020441 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|